Didronel (etidronate) belongs to a bunch of medicines known as bisphosphonates (bis FOS commissioned military officer nayts). It alters the cycle of bone formation and breakdown within the body.
Didronel is employed to treat Paget’s disease, and to treat conditions of irregular bone growth owing to hip fracture orfuniculus injury.
Didronel can also be used for functions ex-directory during this medication guide.
Submit your review
Get emergency medical help if you have any signs of an allergic reaction to Didronel: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using Didronel and call your doctor at once if you have:
painful or difficult swallowing;
severe heartburn, burning pain in your upper stomach, or coughing up blood;
severe joint, bone, or muscle pain;
jaw pain, numbness, or swelling;
severe diarrhea; or
severe skin reaction - fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.
Common Didronel side effects may include:
muscle cramps, joint pain; or
numbness or tingly feeling.
Didronel should be taken as a single, oral dose. As with other bisphosphonates, it is recommended that Didronel should be swallowed with a full glass of water (6 to 8 oz). Patients should not lie down after taking the medication. However, should gastrointestinal discomfort occur, the dose may be divided. To maximize absorption, patients should avoid taking the following items within two hours of dosing: --Food, especially food high in calcium, such as milk or milk products. --Vitamins with mineral supplements or antacids which are high in metals such as calcium, iron, magnesium, or aluminum. Paget's Disease: Initial Treatment Regimens: 5 to 10 mg/kg/day, not to exceed 6 months, or 11 to 20 mg/kg/day, not to exceed 3 months. The recommended initial dose is 5 mg/kg/day for a period not to exceed 6 months. Doses above 10 mg/kg/day should be reserved for when 1) lower doses are ineffective or 2) there is an overriding need to suppress rapid bone turnover (especially when irreversible neurologic damage is possible) or reduce elevated cardiac output. Doses in excess of 20 mg/kg/day are not recommended. Retreatment Guidelines: Retreatment should be initiated only after 1) a Didronel-free period of at least 90 days and 2) there is biochemical, symptomatic or other evidence of active disease process. It is advisable to monitor patients every 3 to 6 months although some patients may go drug free for extended periods. Retreatment regimens are the same as for initial treatment. For most patients the original dose will be adequate for retreatment. If not, consideration should be given to increasing the dose within the recommended guidelines. Heterotopic Ossification: The following treatment regimens have been shown to be effective: --Total Hip Replacement Patients: 20 mg/kg/day for 1 month before and 3 months after surgery (4 months total). --Spinal Cord Injured Patients: 20 mg/kg/day for 2 weeks followed by 10 mg/kg/day for 10 weeks (12 weeks total). Didronel therapy should begin as soon as medically feasible following the injury, preferably prior to evidence of heterotopic ossification.